Cashu
Theravance Biopharma: Navigating Market Dynamics While Advancing Innovative Therapeutics
2 months ago
Stocks
Health Care
tbph
Theravance Biopharma
NASDAQ: TBPH
+0.08 (+0.58%)
13.89
USD
At close at Mar 12, 20:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
695.49M
Dividend Yield
0.00%
P/E Ratio
23.70
EPS
-1.15
Revenue
64.38M
Avg. Volume
1.01M
About
What does TBPH do?
Theravance Biopharma, based in Grand Cayman, focuses on developing respiratory medicines and has 99 employees; its key product, YUPELRI, treats COPD. The company is also developing Ampreloxetine for neurogenic orthostatic hypotension and TD-8954 for gastrointestinal motility disorders.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.